Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 66 entries
Sorted by: Best Match Show Resources per page
Comparison of .

Pharmacogenomics and personalized medicine

Sychev DA, Shuev GN, Suleymanov SS, Ryzhikova KA, Mirzaev KB, Grishina EA, Snalina NE, Sozaeva ZA, Grabuzdov AM, Matsneva IA.
PMID: 28435307
Pharmgenomics Pers Med. 2017 Mar 31;10:93-99. doi: 10.2147/PGPM.S129665. eCollection 2017.

BACKGROUND: The efficiency and safety of drug therapy depends on the peculiarities of functioning of the P450 cytochrome group and transporting proteins. There are significant differences for single-nucleotide polymorphism (SNP) frequency.MATERIALS AND METHODS: We studied the peculiarities of P450...

Cite
Sychev DA, Shuev GN, Suleymanov SS, et al. Comparison of . Pharmgenomics Pers Med. 2017;10:93-99doi: 10.2147/PGPM.S129665.
Sychev, D. A., Shuev, G. N., Suleymanov, S. S., Ryzhikova, K. A., Mirzaev, K. B., Grishina, E. A., Snalina, N. E., Sozaeva, Z. A., Grabuzdov, A. M., & Matsneva, I. A. (2017). Comparison of . Pharmacogenomics and personalized medicine, 1093-99. https://doi.org/10.2147/PGPM.S129665
Sychev, Dmitrij Alekseevitch, et al. "Comparison of ." Pharmacogenomics and personalized medicine vol. 10 (2017): 93-99. doi: https://doi.org/10.2147/PGPM.S129665
Sychev DA, Shuev GN, Suleymanov SS, Ryzhikova KA, Mirzaev KB, Grishina EA, Snalina NE, Sozaeva ZA, Grabuzdov AM, Matsneva IA. Comparison of . Pharmgenomics Pers Med. 2017 Mar 31;10:93-99. doi: 10.2147/PGPM.S129665. eCollection 2017. PMID: 28435307; PMCID: PMC5386602.
Copy Download .nbib Format: NLM
Photoinduced hydrophilic conversion of hydrated ZnO surfaces.

Journal of colloid and interface science

Rudakova AV, Oparicheva UG, Grishina AE, Murashkina AA, Emeline AV, Bahnemann DW.
PMID: 26774972
J Colloid Interface Sci. 2016 Mar 15;466:452-60. doi: 10.1016/j.jcis.2015.08.015. Epub 2015 Aug 06.

Here we focused on the study of the effect of the zinc oxide nano-coatings surface acidity on the surface hydrophilicity and photoinduced hydrophilic conversion. A three-step procedure was used to have the initial state of the ZnO surface free...

Cite
Rudakova AV, Oparicheva UG, Grishina AE, et al. Photoinduced hydrophilic conversion of hydrated ZnO surfaces. J Colloid Interface Sci. 2015;466:452-60doi: 10.1016/j.jcis.2015.08.015.
Rudakova, A. V., Oparicheva, U. G., Grishina, A. E., Murashkina, A. A., Emeline, A. V., & Bahnemann, D. W. (2016). Photoinduced hydrophilic conversion of hydrated ZnO surfaces. Journal of colloid and interface science, 466452-60. https://doi.org/10.1016/j.jcis.2015.08.015
Rudakova, Aida V, et al. "Photoinduced hydrophilic conversion of hydrated ZnO surfaces." Journal of colloid and interface science vol. 466 (2016): 452-60. doi: https://doi.org/10.1016/j.jcis.2015.08.015
Rudakova AV, Oparicheva UG, Grishina AE, Murashkina AA, Emeline AV, Bahnemann DW. Photoinduced hydrophilic conversion of hydrated ZnO surfaces. J Colloid Interface Sci. 2016 Mar 15;466:452-60. doi: 10.1016/j.jcis.2015.08.015. Epub 2015 Aug 06. PMID: 26774972.
Copy Download .nbib Format: NLM
The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction.

Pharmacogenomics and personalized medicine

Zastrozhin MS, Grishina EA, Ryzhikova KA, Smirnov VV, Savchenko LM, Bryun EA, Sychev DA.
PMID: 29343979
Pharmgenomics Pers Med. 2017 Dec 28;11:1-5. doi: 10.2147/PGPM.S144503. eCollection 2018.

BACKGROUND: Isoenzymes CYP2D6 and CYP3A4, the activity of which varies widely, are involved in metabolism of haloperidol and may influence its profile of efficacy and safety.OBJECTIVE: The primary aim of this study was to estimate the relationship between CYP3A5...

Cite
Zastrozhin MS, Grishina EA, Ryzhikova KA, et al. The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. Pharmgenomics Pers Med. 2017;11:1-5doi: 10.2147/PGPM.S144503.
Zastrozhin, M. S., Grishina, E. A., Ryzhikova, K. A., Smirnov, V. V., Savchenko, L. M., Bryun, E. A., & Sychev, D. A. (2018). The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. Pharmacogenomics and personalized medicine, 111-5. https://doi.org/10.2147/PGPM.S144503
Zastrozhin, Mikhail Sergeevich, et al. "The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction." Pharmacogenomics and personalized medicine vol. 11 (2018): 1-5. doi: https://doi.org/10.2147/PGPM.S144503
Zastrozhin MS, Grishina EA, Ryzhikova KA, Smirnov VV, Savchenko LM, Bryun EA, Sychev DA. The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. Pharmgenomics Pers Med. 2017 Dec 28;11:1-5. doi: 10.2147/PGPM.S144503. eCollection 2018. PMID: 29343979; PMCID: PMC5749387.
Copy Download .nbib Format: NLM
CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole.

Pharmacogenomics and personalized medicine

Denisenko NP, Sychev DA, Sizova ZM, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA.
PMID: 29950882
Pharmgenomics Pers Med. 2018 Jun 18;11:107-112. doi: 10.2147/PGPM.S159708. eCollection 2018.

BACKGROUND: Proton pump inhibitors (PPIs) are metabolized by cytochrome P450. CYP2C19 is the main isoenzyme for the majority of PPI, whereas CYP3A family is a secondary enzyme for PPI biotransformation.PURPOSE: The aim of the study was to find if...

Cite
Denisenko NP, Sychev DA, Sizova ZM, et al. CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. Pharmgenomics Pers Med. 2018;11:107-112doi: 10.2147/PGPM.S159708.
Denisenko, N. P., Sychev, D. A., Sizova, Z. M., Smirnov, V. V., Ryzhikova, K. A., Sozaeva, Z. A., & Grishina, E. A. (2018). CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. Pharmacogenomics and personalized medicine, 11107-112. https://doi.org/10.2147/PGPM.S159708
Denisenko, Natalia P, et al. "CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole." Pharmacogenomics and personalized medicine vol. 11 (2018): 107-112. doi: https://doi.org/10.2147/PGPM.S159708
Denisenko NP, Sychev DA, Sizova ZM, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA. CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. Pharmgenomics Pers Med. 2018 Jun 18;11:107-112. doi: 10.2147/PGPM.S159708. eCollection 2018. PMID: 29950882; PMCID: PMC6014385.
Copy Download .nbib Format: NLM
[Multimodular Cognitive Training for Nursing Staff Aged 50+: Initial Results of a Pilot Study on Feasibility and Efficacy].

Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))

Buschert VC, Grishina A, Feichtner A.
PMID: 31394577
Gesundheitswesen. 2020 Nov;82(11):854-860. doi: 10.1055/a-0955-5484. Epub 2019 Aug 08.

THE AIM OF THE STUDY: was the assessment of the feasibility of a cognitive training program for employees of care 50+.METHOD: A cognitive training program (13 h, 5 sessions) was conducted with 15 nurses of the University Hospital Munich...

Cite
Buschert VC, Grishina A, Feichtner A. Multimodulares kognitives Training für Mitarbeiter in der Pflege 50+: Erste Ergebnisse einer Pilotstudie zur Durchführbarkeit und Wirksamkeit. [Multimodular Cognitive Training for Nursing Staff Aged 50+: Initial Results of a Pilot Study on Feasibility and Efficacy]. Gesundheitswesen. 2019;82(11):854-860doi: 10.1055/a-0955-5484.
Buschert, V. C., Grishina, A., & Feichtner, A. (2020). Multimodulares kognitives Training für Mitarbeiter in der Pflege 50+: Erste Ergebnisse einer Pilotstudie zur Durchführbarkeit und Wirksamkeit. [Multimodular Cognitive Training for Nursing Staff Aged 50+: Initial Results of a Pilot Study on Feasibility and Efficacy]. Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)), 82(11), 854-860. https://doi.org/10.1055/a-0955-5484
Buschert, Verena Caroline, et al. "Multimodulares kognitives Training für Mitarbeiter in der Pflege 50+: Erste Ergebnisse einer Pilotstudie zur Durchführbarkeit und Wirksamkeit." [Multimodular Cognitive Training for Nursing Staff Aged 50+: Initial Results of a Pilot Study on Feasibility and Efficacy]. Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) vol. 82,11 (2020): 854-860. doi: https://doi.org/10.1055/a-0955-5484
Buschert VC, Grishina A, Feichtner A. Multimodulares kognitives Training für Mitarbeiter in der Pflege 50+: Erste Ergebnisse einer Pilotstudie zur Durchführbarkeit und Wirksamkeit. [Multimodular Cognitive Training for Nursing Staff Aged 50+: Initial Results of a Pilot Study on Feasibility and Efficacy]. Gesundheitswesen. 2020 Nov;82(11):854-860. doi: 10.1055/a-0955-5484. Epub 2019 Aug 08. German. PMID: 31394577.
Copy Download .nbib Format: NLM
[No title available]

Pharmacogenomics and personalized medicine

Sychev DA, Baturina OA, Mirzaev KB, Rytkin E, Ivashchenko DV, Andreev DA, Ryzhikova KA, Grishina EA, Bochkov PO, Shevchenko RV.
PMID: 32158254
Pharmgenomics Pers Med. 2020 Jan 23;13:29-37. doi: 10.2147/PGPM.S234910. eCollection 2020.

INTRODUCTION: The aim of this study is to assess the influence of gene METHODS: In the multicenter prospective registry study of the efficacy and safety of a combined antithrombotic therapy 103 patients with non-valvular atrial fibrillation both undergoing or...

Cite
Sychev DA, Baturina OA, Mirzaev KB, et al. . Pharmgenomics Pers Med. 2020;13:29-37doi: 10.2147/PGPM.S234910.
Sychev, D. A., Baturina, O. A., Mirzaev, K. B., Rytkin, E., Ivashchenko, D. V., Andreev, D. A., Ryzhikova, K. A., Grishina, E. A., Bochkov, P. O., & Shevchenko, R. V. (2020). . Pharmacogenomics and personalized medicine, 1329-37. https://doi.org/10.2147/PGPM.S234910
Sychev, D A, et al. "." Pharmacogenomics and personalized medicine vol. 13 (2020): 29-37. doi: https://doi.org/10.2147/PGPM.S234910
Sychev DA, Baturina OA, Mirzaev KB, Rytkin E, Ivashchenko DV, Andreev DA, Ryzhikova KA, Grishina EA, Bochkov PO, Shevchenko RV. . Pharmgenomics Pers Med. 2020 Jan 23;13:29-37. doi: 10.2147/PGPM.S234910. eCollection 2020. PMID: 32158254; PMCID: PMC6986167.
Copy Download .nbib Format: NLM
Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder.

Pharmacogenomics and personalized medicine

Zastrozhin MS, Grishina EA, Denisenko NP, Skryabin VY, Markov DD, Savchenko LM, Bryun EA, Sychev DA.
PMID: 29988737
Pharmgenomics Pers Med. 2018 Jun 29;11:113-119. doi: 10.2147/PGPM.S160763. eCollection 2018.

BACKGROUND: Fluvoxamine therapy is used for treatment of patients with depressive disorder, but it is often ineffective, and some patients suffer from dose-dependent undesirable side effects such as vertigo, headache, indigestion, xerostomia, increased anxiety, etc. CYP2D6 is involved in...

Cite
Zastrozhin MS, Grishina EA, Denisenko NP, et al. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmgenomics Pers Med. 2018;11:113-119doi: 10.2147/PGPM.S160763.
Zastrozhin, M. S., Grishina, E. A., Denisenko, N. P., Skryabin, V. Y., Markov, D. D., Savchenko, L. M., Bryun, E. A., & Sychev, D. A. (2018). Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmacogenomics and personalized medicine, 11113-119. https://doi.org/10.2147/PGPM.S160763
Zastrozhin, Mikhail Sergeevich, et al. "Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder." Pharmacogenomics and personalized medicine vol. 11 (2018): 113-119. doi: https://doi.org/10.2147/PGPM.S160763
Zastrozhin MS, Grishina EA, Denisenko NP, Skryabin VY, Markov DD, Savchenko LM, Bryun EA, Sychev DA. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmgenomics Pers Med. 2018 Jun 29;11:113-119. doi: 10.2147/PGPM.S160763. eCollection 2018. PMID: 29988737; PMCID: PMC6029588.
Copy Download .nbib Format: NLM
Reasons for Reduced Moisture Resistance of Sulfur-Extended Asphalt Concrete.

Materials (Basel, Switzerland)

Le HT, Korolev EV, Grishina AN, Gladkikh VA.
PMID: 34885371
Materials (Basel). 2021 Nov 26;14(23). doi: 10.3390/ma14237218.

The paper presents the results of a study of the mechanism for reducing the moisture resistance of sulfur-extended asphalt concrete. It is shown that a decrease in moisture resistance occurs due to the occurrence of chemical and physical processes....

Cite
Le HT, Korolev EV, Grishina AN, et al. Reasons for Reduced Moisture Resistance of Sulfur-Extended Asphalt Concrete. Materials (Basel). 2021;14(23)doi: 10.3390/ma14237218.
Le, H. T., Korolev, E. V., Grishina, A. N., & Gladkikh, V. A. (2021). Reasons for Reduced Moisture Resistance of Sulfur-Extended Asphalt Concrete. Materials (Basel, Switzerland), 14(23), . https://doi.org/10.3390/ma14237218
Le, Huu Tuan, et al. "Reasons for Reduced Moisture Resistance of Sulfur-Extended Asphalt Concrete." Materials (Basel, Switzerland) vol. 14,23 (2021). doi: https://doi.org/10.3390/ma14237218
Le HT, Korolev EV, Grishina AN, Gladkikh VA. Reasons for Reduced Moisture Resistance of Sulfur-Extended Asphalt Concrete. Materials (Basel). 2021 Nov 26;14(23). doi: 10.3390/ma14237218. PMID: 34885371.
Copy Download .nbib Format: NLM
Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder.

Psychopharmacology bulletin

Zastrozhin MS, Skryabin V, Smirnov V, Zastrozhina AK, Kaverina EV, Klepikov DA, Grishina EA, Ryzhikova KA, Bure IV, Bryun EA, Sychev DA.
PMID: 34092821
Psychopharmacol Bull. 2021 Mar 16;51(2):31-42.

INTRODUCTION: Mirtazapine is commonly administered to patients with recurrent depressive disorder. Some of these patients do not show adequate response to the therapy with mirtazapine, whereas many of them experience dose-dependent adverse drug reactions. Previous research revealed that CYP2D6...

Cite
Zastrozhin MS, Skryabin V, Smirnov V, et al. Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. Psychopharmacol Bull. 2021;51(2):31-42
Zastrozhin, M. S., Skryabin, V., Smirnov, V., Zastrozhina, A. K., Kaverina, E. V., Klepikov, D. A., Grishina, E. A., Ryzhikova, K. A., Bure, I. V., Bryun, E. A., & Sychev, D. A. (2021). Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. Psychopharmacology bulletin, 51(2), 31-42.
Zastrozhin, M S, et al. "Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder." Psychopharmacology bulletin vol. 51,2 (2021): 31-42.
Zastrozhin MS, Skryabin V, Smirnov V, Zastrozhina AK, Kaverina EV, Klepikov DA, Grishina EA, Ryzhikova KA, Bure IV, Bryun EA, Sychev DA. Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. Psychopharmacol Bull. 2021 Mar 16;51(2):31-42. PMID: 34092821; PMCID: PMC8146558.
Copy Download .nbib Format: NLM
Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder.

Psychopharmacology bulletin

Zastrozhin MS, Skryabin V, Smirnov V, Zastrozhina AK, Kaverina EV, Klepikov DA, Grishina EA, Ryzhikova KA, Bure IV, Bryun EA, Sychev DA.
PMID: 34092821
Psychopharmacol Bull. 2021 Mar 16;51(2):31-42.

INTRODUCTION: Mirtazapine is commonly administered to patients with recurrent depressive disorder. Some of these patients do not show adequate response to the therapy with mirtazapine, whereas many of them experience dose-dependent adverse drug reactions. Previous research revealed that CYP2D6...

Cite
Zastrozhin MS, Skryabin V, Smirnov V, et al. Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. Psychopharmacol Bull. 2021;51(2):31-42
Zastrozhin, M. S., Skryabin, V., Smirnov, V., Zastrozhina, A. K., Kaverina, E. V., Klepikov, D. A., Grishina, E. A., Ryzhikova, K. A., Bure, I. V., Bryun, E. A., & Sychev, D. A. (2021). Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. Psychopharmacology bulletin, 51(2), 31-42.
Zastrozhin, M S, et al. "Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder." Psychopharmacology bulletin vol. 51,2 (2021): 31-42.
Zastrozhin MS, Skryabin V, Smirnov V, Zastrozhina AK, Kaverina EV, Klepikov DA, Grishina EA, Ryzhikova KA, Bure IV, Bryun EA, Sychev DA. Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. Psychopharmacol Bull. 2021 Mar 16;51(2):31-42. PMID: 34092821; PMCID: PMC8146558.
Copy Download .nbib Format: NLM
Exploring potential inhibitors against Kyasanur forest disease by utilizing molecular dynamics simulations and ensemble docking.

Journal of biomolecular structure & dynamics

Kandagalla S, Novak J, Shekarappa SB, Grishina MA, Potemkin VA, Kumbar B.
PMID: 34662258
J Biomol Struct Dyn. 2021 Oct 18;1-17. doi: 10.1080/07391102.2021.1990131. Epub 2021 Oct 18.

Kyasanur forest disease (KFD) is a tick-borne, neglected tropical disease, caused by KFD virus (KFDV) which belongs to

Cite
Kandagalla S, Novak J, Shekarappa SB, et al. Exploring potential inhibitors against Kyasanur forest disease by utilizing molecular dynamics simulations and ensemble docking. J Biomol Struct Dyn. 2021;1-17doi: 10.1080/07391102.2021.1990131.
Kandagalla, S., Novak, J., Shekarappa, S. B., Grishina, M. A., Potemkin, V. A., & Kumbar, B. (2021). Exploring potential inhibitors against Kyasanur forest disease by utilizing molecular dynamics simulations and ensemble docking. Journal of biomolecular structure & dynamics, 1-17. https://doi.org/10.1080/07391102.2021.1990131
Kandagalla, Shivananda, et al. "Exploring potential inhibitors against Kyasanur forest disease by utilizing molecular dynamics simulations and ensemble docking." Journal of biomolecular structure & dynamics vol. (2021): 1-17. doi: https://doi.org/10.1080/07391102.2021.1990131
Kandagalla S, Novak J, Shekarappa SB, Grishina MA, Potemkin VA, Kumbar B. Exploring potential inhibitors against Kyasanur forest disease by utilizing molecular dynamics simulations and ensemble docking. J Biomol Struct Dyn. 2021 Oct 18;1-17. doi: 10.1080/07391102.2021.1990131. Epub 2021 Oct 18. PMID: 34662258.
Copy Download .nbib Format: NLM
Correction: Novel cationic 1,2,4-selenadiazoles: synthesis .

Dalton transactions (Cambridge, England : 2003)

Khrustalev VN, Grishina MM, Matsulevich ZV, Lukiyanova JM, Borisova GN, Osmanov VK, Novikov AS, Kirichuk AA, Borisov AV, Solari E, Tskhovrebov AG.
PMID: 34494059
Dalton Trans. 2021 Sep 21;50(36):12730. doi: 10.1039/d1dt90151f.

Correction for 'Novel cationic 1,2,4-selenadiazoles: synthesis

Cite
Khrustalev VN, Grishina MM, Matsulevich ZV, et al. Correction: Novel cationic 1,2,4-selenadiazoles: synthesis . Dalton Trans. 2021;50(36):12730doi: 10.1039/d1dt90151f.
Khrustalev, V. N., Grishina, M. M., Matsulevich, Z. V., Lukiyanova, J. M., Borisova, G. N., Osmanov, V. K., Novikov, A. S., Kirichuk, A. A., Borisov, A. V., Solari, E., & Tskhovrebov, A. G. (2021). Correction: Novel cationic 1,2,4-selenadiazoles: synthesis . Dalton transactions (Cambridge, England : 2003), 50(36), 12730. https://doi.org/10.1039/d1dt90151f
Khrustalev, Victor N, et al. "Correction: Novel cationic 1,2,4-selenadiazoles: synthesis ." Dalton transactions (Cambridge, England : 2003) vol. 50,36 (2021): 12730. doi: https://doi.org/10.1039/d1dt90151f
Khrustalev VN, Grishina MM, Matsulevich ZV, Lukiyanova JM, Borisova GN, Osmanov VK, Novikov AS, Kirichuk AA, Borisov AV, Solari E, Tskhovrebov AG. Correction: Novel cationic 1,2,4-selenadiazoles: synthesis . Dalton Trans. 2021 Sep 21;50(36):12730. doi: 10.1039/d1dt90151f. PMID: 34494059.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 66 entries